Conflict of Interest

The author has declared no conflict of interest.

TB Practecal Innovating MDR-TB Treatment

Early termination of randomisation into TB-PRACTECAL, a novel six month, all-oral regimen study.

Bern-Thomas Nyang'wa, <u>Catherine Berry</u>, Ilaria Motta, Emil Kazounis

This study was approved by the London School of Hygiene and Tropical Medicine Ethics Review Board (ERB) and the MSF Ethics Review Board, as well as national or regional ERB's at each trial site. Clinicaltrials.gov registry number, NCT02589782.








Principles for designing future regimens for multidrugresistant tuberculosis

Grania Brigden,^a Bern-Thomas Nyang'wa,^b Philipp du Cros,^b Francis Varaine,^c Jennifer Hughes,^d Michael Rich,^e C Robert Horsburgh Jr,^f Carole D Mitnick,^g Eric Nuermberger,^h Helen McIlleron,ⁱ Patrick PJ Phillips^j & Manica Balasegaram^a

- At least one new class
- At least three and max five effective drugs
- Effective against multidrug-resistant (MDR) and pre-extensively drug-resistant (XDR) strains
- 6-9 months, all oral
- Good side effect profile, limited monitoring
- Minimal interaction with antiretrovirals







2





One day of MDR/ pre-XDR regimen today

'A randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of drug regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug resistant tuberculosis'





One day of TB PRACTECAL arm-1







Investigational arms:

1.Bedaquiline + Pretomanid + linezolid + moxifloxacin

2.Bedaquiline + Pretomanid + linezolid + clofazimine

- 3.Bedaquiline + Pretomand + linezolid
 - For 24 weeks

Control arm:

Locally accepted standard of care (SOC) which is consistent with the WHO recommendations for the treatment of M/XDR-TB

- For 36 96 weeks
- Included shorter MDR-TB regimen and bedaquiline / delaminid containing regimens



Tablets









Population


- ≥15 years of age
- Regardless of HIV status
- Microbiological test (molecular or phenotypic) confirming presence of M. tuberculosis
- Resistant to at least rifampicin by either molecular or phenotypic drug susceptibility test
- Can include pre-XDR (fluoroquinolone resistance)





5





EDECINS SANS FRONTIERES

DOCTORS WITHOUT BORDERS

elarus	South Africa	Uzbekistan
(35-40)	3.4 (2.5-4.3)	12 (11-13)
344	406	602
7.1%	58%	4%
70%	60%	61%



*2020 Global Tuberculosis report, Accessed 7th May 2021



Stage 1

Primary objective:

on safety and efficacy outcomes after 8 weeks of treatment

Primary outcomes:

- Analysis at stage 1 was based on investigational arms only; no SOC
- The sample size of 60 participants per arm was based on the number required to detect:
 - a percentage culture conversion < 40% and / or
 - an investigational arm.



Identify regimens containing bedaquiline and pretomanid for further evaluation based

a percentage of treatment discontinuation for any cause and death >45% in





- Primary outcome: composite of death, treatment discontinuation, lost to follow up, treatment failure, recurrence or withdrawal
- 1 or 2 investigational arms compared against SOC
- Non-inferiority design
 - a delta of 12%
 - a conservative alpha of 1.7% (corresponding to 1-sided CI 98.3%)
 - 181 patients to give 85% power
 - Allowing for 10% non-assessable = 201 patients per arm




Stage 2





Stage 1 \rightarrow 2 decision






SUDVI SCIE

Time points in weeks





Trial Milestones











Data safety monitoring board (DSMB) review

- Review of safety and efficacy data February 2021.
 - data lock was 31 December 2020
- Data from:
 - 122 participants in the control arm
 - 120 in an experimental arm 1
 - with "late exclusions" removed from efficacy analyses.
- Data also provided for 229 participants in experimental arms 2 and 3, but these arms have been discontinued from enrollment in Stage 2 of the study.







DSMB Recommendation

- "Based on their review, the DSMB unanimously recommends termination of randomization of new participants in the trial.
- This recommendation is based primarily on guidance in the DSMB Charter that stopping might be considered if a difference between randomized arms of at least 3 standard deviations in the interim analysis of a major endpoint is achieved and the results have the potential to impact clinical practice."







DSMB Recommendation

- achieved favouring the experimental arm being evaluated in Stage 2 (PRACTECAL arm-1) versus the standard of care control arm for the primary outcome of percentage of study participants with an unfavourable outcome.
- the control arm.

Outcome	Arm 1	Control arm
Death	0	5
Recurrence	0	0
TB treatment failure	0	0



Specifically, the DSMB considers that this level of evidence was

• The difference in the proportion of unfavourable outcomes was primarily driven by a higher rate of treatment discontinuations in





Outcomes/Conclusions

- On 18th March, 2021, recruitment was terminated, follow-up ongoing
- Completion of data checking, cleaning and update to provide to WHO
- TB-PRACTECAL regimen 1 and other 6-9 month regimens will be assessed by WHO in 2021 guidelines review
- MSF is currently developing guidance and collaborations to scale up the regimen







A Global Collaboration

- Médecins Sans Frontières
- Swiss Tropical & Public Health Institute
- London School of Hygiene and Tropical Medicine
- University College London
- Global Alliance for TB Drug Development
 TB & HIV Investigative Network (THINK)
- Drugs for Neglected Diseases Initiative
- eResearch Technology, Inc.;
- Ministry of Health, Republic of Uzbekistan
- Ministry of Health, Belarus



Swiss Tropical and Public Health Institute













With special acknowledgement of our participants

Questions? TB-PRACTECAL@london.msf.org





- Republican Specialised Scientific Practical Medical Centre of Tuberculosis and Pulmonology (TBI)
- Republican Scientific and Practical Centre for Pulmonology and Tuberculosis (RSPCPT)
- Clinical HIV Research Unit, Wits Health Consortium
- TDR, Special Programme for Research and Training in Tropical Diseases



















